glp 1 agonist mechanism GLP-1 Receptor Agonists as Treatments for Type 2 Diabetes The Impact of GLP-1 Receptor

Design, synthesis and biological evaluation of hetero-aromatic moieties substituted pyrrole-2-carbonitrile derivatives as dipeptidyl peptidase IV inhibitors

While the study found that semaglutide specifically reduced the risk of atrial arrhythmias and atrial fibrillation (AF), other studies have reported conflicting results regarding the arrhythmia risk associated with GLP-1 RAs (91)

At the American College of Cardiology meetings today, with simultaneous publication in NEJM, was a new randomized trial of semaglutide in 616 participants with heart failure with preserved ejection fraction, obesity and Type 2 diabetes

Another characteristic of study design that might confound comparisons between different agents is the temporal difference in excluding patients in the early post-MI period